MOMENT ANALYSIS FOR THE EVALUATION OF IN VITRO AND IN VIVO BIOAVAILABILITY OF THEOPHYLLINE MICROCAPSULES*

SHAN-YANG LIN # and JUEI-CHYI YANG

Biopharmaceutics Laboratory, Department Medical Research, Veterans General Hospital, Shih-Pai, Taipei, Taiwan, Republic of China

ABSTRACT

Statistical moment analysis has been to establish an in vitro-in vivo correlation for of theophylline ethylcellulose microcapsules prepared by using various concentrations of acetate vinyl (EVA) copolymer as а coacervation-The concentration of EVA copolymer was inducing agent. found to be played an important function controlled release of theophylline microcapsules. Correlations were found between the in dissolution behavior, e.g., MDT $0 \rightarrow 7$, in vitro, and the

Correspondence

805

Copyright © 1988 by Marcel Dekker, Inc.



is XV paper part of "Studies on Microencapsulation"

rate of bioavailability, e.g., Cmax, Tmax, MDT although there was no valid correlation with the extent of bioavailability, e.g., moment analysis by studying the quantitative in vitro-in vivo correlations relating to drug release was validated.

INTRODUCTION

Statistical moment analysis has recently developed and used as a noncompartmental approach biopharmaceutical evaluations (1-4).The mean (MRT) concept has been defined time residence the rate of bioavailability and magnitude of employed for the evaluation of the in vitro dissolution time (5). Recently, moment analysis been suggested as a valuable method in studies quantitative in vitro-in vivo correlations related drug release (6).

We have previously determined that theophylline ethylcellulose microcapsules prepared bу ethylene-vinyl acetate (EVA) copolymer coacervation-inducing agent, showed a sustained release behavior in vitro and in vivo, but this was dependent on the concentrations of the coacervation-inducing agent used (7-9). The compression force and excipients



significantly influenced the tablet properties used and dissolution behavior of the compressed theophylline microcapsules, however, the particle size microcapsules appeared less dependent (10).

aim of this study is to investigate statistical moment analysis is applicable in vitro-in vivo correlation of theophylline ethylcellulose microcapsules.

MATERIALS and METHODS

Materials:

Theophylline anhydrous powder was obtained Wako Pure Chem. Co.(Tokyo, Japan). Ethylene-vinyl acetate (EVA, VA content: 28%) was obtained from Toyo Soda Manufacturing Co. (Tokyo, Japan). Ethylcellulose (100 cps) was purchased from Dow Chem. Co. (MI., USP). The remaining reagents were analytical reagent grade. The Sprague-Dawley rats were male rats purchased from the Animal Center of National Yangming Medical College, Taiwan, ROC and weighed 300-350 g.

Dosage forms:

Five different types of theophylline microcapsules were prepared by the phase separation method using five concentrations (0, 0.85, 1.7, 3.3 and 5%) of copolymer as a coacervation-inducing agent,



250-450 um of described in previous studies (11-13). particle size theophylline microcapsules were used this experiment.

In vitro dissolution studies:

The in vitro dissolution rates for the theophylline in 500 ml of pH 1.2 medium at 37°C microcapsules determined by using the rotating basket method Aliquots of the rpm), according to USP XXI. medium were assayed for theophylline by dissolution ultraviolet spectrophotometer at 270 nm (UVIKON Switzerland). Each test was carried out Kontron, triplicate.

In vivo bioavailability studies:

SD rats were fasted from the night before The throughout the experiment. Each dosage form was tested 6-8 SD rats. Each rat was respectively in male administered a dose of 40 mg/kg of theophylline powder or an equivalent dose in microcapsules form. The test sample was given orally with 10 ml of water a feeding tube. Blood samples were collected at postdosing from a cannula the prescribed time arteria jugularis. The samples were centrifuged, was removed and stored at -20°C until analysis. serum



Theophylline concentrations in the serum were determined by EMIT method (Syva).

Data analysis:

<u>In vitro:</u>

If the dissolution process in vitro is regarded as statistically randomized variables, a moment analysis be used for the description of the time (5).The in vitro mean dissolution), describing the first moment of the (MDT in vitro dissolution rate-time curve, is defined as follows (14).

MDT in vitro =
$$\int_0^\infty t(dm/dt)dt/\int_0^\infty (dm/dt)dt$$
 (1)

where (dm/dt) is the time function of the dissolution second moment of the concentration time rate. curve can be used to define the in vitro variance of dissolution time ($\mbox{VDT}_{\mbox{in vitro}}$).

VDT in vitro =
$$\int_{0}^{\infty} (t-MDT)^{2} \frac{dAD(t)}{dt} dt / \int_{0}^{\infty} \frac{dAD(t)}{dt} dt$$
 (2)

<u>In vivo:</u>

biopharmaceutical parameters (Cmax, Tmax and $AUC_{0\rightarrow 27}$) were determined from the serum concentration of theophylline after a single dose administration. chosen Cmax as the highest observed was theophylline concentration and Tmax was the time of the



maximum measured serum concentration. calculated by using the trapezoidal rule from zero to 27 hours.

The time course of plasma concentration following a single dose is usually regarded as statistical distribution curve (1). The in vivo residence time (MRT) is defined as the mean time drug molecules to transit through the body, involves the in vivo release kinetic from the dosage absorption into the body and all disposition processes. The MRT is calculated from the ratio between the area under the first moment of the plasma concentration curve and the area under the zero moment:

$$MRT = \int_0^\infty tCp \ dt / \int_0^\infty Cp \ dt$$
 (3)

variance of residence of a drug in the body is defined as followed.

$$VRT = \int_0^\infty (t - MRT)^2 Cp dt / \int_0^\infty Cp dt$$
 (4)

in vivo mean dissolution time (MDT $_{in\ vivo}$) microcapsules in the body is calculated according to Eq. 5:

MDT in vivo = MRT microcapsules - MRT solution

 $\ensuremath{\mathsf{MRT}}\xspace_{\ensuremath{\mathsf{microcapsules}}}$ and $\ensuremath{\mathsf{MRT}}\xspace_{\ensuremath{\mathsf{solution}}}$ are the Where



residence time for the microcapsules and the solution, respectively.

using the above equations, the moments were calculated by means of the trapezoidal integration the time course curve. The moments obtained from experimental data were carried out on a personal computer with programming in BASIC. Data are expressed the mean and standard error (S.E.). Student's t-test was used for statistical analysis.

RESULTS and DISCUSSION

biopharmaceutical parameters (Cmax, AUC $_{0\rightarrow27}$) were determined from the serum theophylline profiles after single concentration time administration of theophylline microcapsules. vitro mean dissolution time, MDT $_{0\rightarrow7}$, in vitro describing the first moment of the dissolution time curve is also calculated from Eq. 1. Fig. 1 shows relationship between the biopharmaceutical parameters and MDT $_{0\rightarrow7}$, in vitro It is obvious that were statistically significant correlations there between Cmax and MDT $_{0\rightarrow7}$, in vitro (r=0.9426), and Tmax and MDT $_{0\rightarrow7}$, in vitro (r=0.9647); whereas AUC $_{0\rightarrow27}$ and MDT $_{0\rightarrow7,in\ vitro}$ (r=0.0863) showed no correlation. This implies that in vitro mean dissolution time correlated






FIG. 1 Correlation of MDT with Tmax, Cmax and AUC of theophylline microcapsules Key: \bigcirc , 0%; \triangle , 0.83%; \square , 1.7%; \bullet , 3.3%; \triangle , 5%; the bars indicate SEM

Cmax and Tmax, which corresponds to with of absorption, than with AUC $_{0\rightarrow27}$ which The no valid correlation extents of absorption. the in vitro mean dissolution time and extent may be due to the fact that the extent absorption absorption was significantly affected by the physiological factors in the GI tract, compared to the rate of absorption (9,15).

effect of EVA concentrations on the moment dissolution curves (MDT $_{0\rightarrow7}$, in vitro, VDT $_{0\rightarrow7}$, in vitro and moment of serum concentration profiles (MRT $_{0\rightarrow27}$ and $VRT_{0\rightarrow27}$) are shown in Figs. 2 and 3, respectively. sigmoid curve is found in Fig. 2, whereas a good 3. relation is found in Fig. The the linear






FIG. 2 The effect of EVA copolymer concentration used on the MDT and VDT of the phylline microcapsules

concentration of EVA copolymer, the higher the value of The result suggests that MRT and moment parameters. MDT significantly depend on the concentration of **EVA** copolymer used. This implies that the concentration of EVA copolymer plays an important function the of theophylline microcapsules controlled release in vitro and in vivo.







FIG. 3

The effect of EVA copolymer concentration used on the MRT and VRT of theophylline microcapsules Key: see FIG. 1

MRT _{0→27} and relationship between The different types of the $MDT_{0\rightarrow7}$, in vitro microcapsules is shown in Fig. 4. The mean regression line was found to be $MRT_{0\rightarrow27} = 1.937 \text{ MDT}_{0\rightarrow7}$, in vitro 5.889, the correlation coefficient (r) was result indicates that there is a quantitative vitro-in vivo correlation for theophylline which is





Key: see FIG. 1

FIG. 4

Correlation between MRT and MDT for theophylline microcapsules

encapsulated into microcapsule dosage form. The intercept on the y-axis, 5.88, can be interpreted as in vivo residence time for an oral aqueous mean solution, MRT_{solution} . The value of MRT _{solution} was substitued into Eq. 5 and the data of MDT $_{\mbox{in vivo}}$ was obtained. A linear relationship was also obtained



for theophylline microcapsules between mean dissolution vivo and in vitro when applying statistical in moment analysis.

the above results, it is obvious that moment easily help to establish correlation can analysis the in vitro dissolution behavior and in between theophylline release of sustained bioavailability microcapsules.

REFERENCES

- 1. K. Yamaoka, T. Nakagawa and T. Uno, J. Pharmacokin. Biopharm., 6, 547-558 (1978)
- 2. Y. Tanigawara, K. Yamaoka, T. Nakagawa and T. Uno, J. Pharm. Sci., 71, 1129-1133 (1982)
- M. Nicklasson and J. E. Lindgren, J. Graffner, Pharmacoki. Biopharm., 12, 367-380 (1984)
- ₽. Collier, J. Pharmacoki. 4. S. Riegelman and Biopharm., 8, 509-534 (1980)
- Tanigawara, K. Yamaoka, T. Nakagawa and T. Uno, Chem. Pharm. Bull., 30, 1088-1090 (1982)
- Eckert, Acta Pharm. Technol., 29, 6. W. Emi and Μ. 281-286 (1983)
- 7. S. Y. Lin and J. C. Yang, J. Microencapsulation, 2, 315-325 (1985)
- 8. S. Y. Lin and J. C. Yang, J. Taiwan Pharm. Assoc., 38, 160-165 (1986)
- 9. S. Y. Lin and J. C. Yang, J. Pharm. Sci., 76, 219-223 (1987)
- Abstract in the 14th Inter. Sym. Lin, Toronto, Control. Release of Bioactive Materials, Canada, 1987.



- 11. S. Υ. Lin, J. C. Yang and S. S. Jiang, J. Taiwan Pharm. Assoc., 37, 1-10 (1985)
- 12. S. Y. Lin, J. Microencapsulation, 2, 91-101 (1985)
- 13. S. Y. Lin and J. C. Yang, J. Controlled Release, 3, 221-228 (1986)
- 14. Y. Tanigawara, K. Yamaoka, T. Nakagawa, M. Nakagawa and T. Uno, J. Pharm. Dyn., 5, 370-372 (1982)
- 15. N. Aoyagi, H. Ogata, N. Kaniwa, A. Ejima, Int. J. Clin. Pharmcol. Ther. Toxic., 23, 529-534 (1985)

